Latest news with #NewFrontiers
Irish Times
01-05-2025
- Business
- Irish Times
Developing next generation enzymes to underpin industries from food to therapeutic drugs
'Enzymes are the hardest working molecules in nature. They have a role to play in countless bioprocesses from the production of bioethanol, drugs and detergents to brewing, baking and food – and that's only scratching the surface,' explains Dr Tim Roche. Roche is co-founder of BioEnz Technologies , which is developing a commercial portfolio of novel enzymes that will play a key role in protecting the environment , improving nutrition and treating disease in the future. BioEnz is a B2B business which was spun out of SETU , (Waterford's South East Technological University), in December 2019. Before the company could even get out of the starting blocks, it was stymied by the arrival of Covid which saw potential customers lose their appetite for noncore activities. BioEnz had no choice but to sit tight until sentiment improved and it was effectively 2024 before the company could make a splash with its first product, a proprietary enzyme called cellobiase. READ MORE Its function is to enhance the commercial production of bioethanol by breaking down the cellulose (found in the raw materials) more efficiently. The enzyme is currently in pilot testing, with full market launch slated for Q3 this year. 'The idea for the business grew from a realisation of the challenges enzyme suppliers face in identifying next generation enzymes to deliver greater energy efficiencies, improved yields and cleaner bio-processes,' says Roche. 'Our customers are enzyme suppliers who are coming under increased pressure from their customers to provide solutions that are cleaner, greener and more cost effective. If they tell us where their discovery pain points are, we can help them find a way through. 'No company has all the solutions and every product has a life cycle that ages with diminishing returns and needs to be refreshed or replaced.' BioEnz's founding team of four includes Dr Lee Coffey, a molecular biologist with more than 20 years' experience in enzyme discovery and Dr Karen Tambling, who has a background in microbiology and biopharmaceuticals. Roche is a plant scientist with three decades of biotechnology commercialisation under his belt, while the fourth founder, Jens Bleiel, also has a long track record in applying scientific research in commercial settings. [ Three little letters that could help transform the Irish economy: PhD Opens in new window ] To date, around €1 million has been invested in the company, with financial support from Enterprise Ireland through its pre-seed start fund and the New Frontiers programme at the Rubicon in Cork, while the South East Business & Innovation Centre provided the company with mentoring under the Propeller Prep4seed programme. The company will make its money through a combination of licence fees and royalties and will have two routes to market. It will develop its own products for different sectors and undertake bespoke enzyme development for individual customers. BioEnz hired its first full-time employee last year and employment at the company is expected to reach 21 people by 2028. The next step is to begin 'actively seeking substantial investment', says Roche, who adds that the company is poised to disrupt the enzymes market – in a positive way. 'Disrupters are people who are uncomfortable with comfort and complacency and there is definitely a need for some subversion,' he says. 'Business cannot continue the way it's going as it's damaging the environment and becoming less profitable. Companies need to do things better and generate more value. 'This is where we can make a meaningful contribution. The companies that have been most successful up to now are, arguably, the ones that have been the most agile in reforming and realigning their supply chains and forming strategic partnerships that are based on an R&D capability they don't currently have. 'We have a number of target markets in mind and there is no shortage of opportunity,' Roche adds. 'We have started with the biofuels sector, but we are keen to expand our portfolio and are developing enzyme solutions for food allergen removal, plastic decomposition and therapeutic applications.'
Sharjah 24
29-04-2025
- Science
- Sharjah 24
UAE President receives participants in Behavioural Exchange 2025
The conference, organised by the Office of Development Affairs, will take place from 30 April to 1 May 2025 at NYU Abu Dhabi under the theme 'New Frontiers in Behavioural Science'. President His Highness emphasised that community engagement, support, and positivity are essential to the success of development-focused initiatives, particularly in areas such as education, healthcare, climate action, and sustainability. His Highness reaffirmed the UAE's firm commitment to promoting good conduct within society as a key element in advancing development plans. Participants in the conference expressed their gratitude to His Highness the President for the UAE's hosting of the event and praised the country's continued development across various fields.
CairoScene
14-04-2025
- Science
- CairoScene
Abu Dhabi to Host Global Behavioural Science Conference BX2025
Set to be the first MENA edition of the conference, BX2025 will explore how behavioural insights shape public policy. Apr 14, 2025 Abu Dhabi is set to become the first city in the MENA region to host the Behavioural Exchange (BX2025) conference, the world's leading forum on the application of behavioural science in public policy. Organised by the Behavioural Insights Team (BIT) and the Behavioural Science Group, the conference will take place from April 30th to May 1st at New York University Abu Dhabi under the theme 'New Frontiers for Behavioural Science'. BX2025 brings together global experts, policymakers, academics, and practitioners to examine how behavioural insights can inform effective governance. This year's edition will explore how behavioural science can address emerging societal challenges, from health and education to environmental sustainability and financial well-being. Behavioural science, rooted in the study of decision-making and human psychology, has become a powerful tool in shaping effective public policy. Governments around the world increasingly use behavioural insights to design interventions that align with how people actually think and behave, rather than how they are expected to. The conference, now in its seventh edition, has previously been held in cities including London, New York, and Sydney. The Abu Dhabi edition signifies the UAE's growing investment in evidence-based policy and its role as a regional hub for research and innovation. Registration for BX2025 is now open via the event's official website.
Associated Press
14-03-2025
- Health
- Associated Press
Planet TV Studios to Feature Dr. Daniel C. Allison in New Frontiers Episode Airing March 15th 2025 on Bloomberg. The content in the episode is a Planet TV Studios Original and it is brought to you by and sponsored by Planet TV Studios
Planet TV Studios proudly serves as the exclusive sponsor of the New Frontiers series. Dr. Daniel C. Allison in New Frontiers Episode March 15th on Bloomberg Television. LOS ANGELES, CA, UNITED STATES, March 14, 2025 / / -- Planet TV Studios is airing an incisive look at transformative medical technology on Bloomberg Television this Saturday, March 15th, 2025, from 5:00 to 5:30 pm ET. The program, part of the New Frontiers series and aptly retitled 'New Frontiers: Highlighting Emerging Technologies', offers an in-depth exploration of advancements that are reshaping medical science. At the center of this episode is Dr. Daniel C. Allison, MD, FACS—a board-certified orthopedic surgeon whose work in musculoskeletal oncology and complex skeletal reconstruction has consistently pushed the envelope in surgical innovation. Dr. Allison has not only led as Assistant Director of Orthopedic Oncology at Cedars-Sinai Medical Center and Co-Director of Pediatric Orthopedic Oncology at Children's Hospital Los Angeles, but he has also developed procedures that have markedly improved patient outcomes. His unparalleled work includes being the first in Southern California to perform osseointegration implant surgery on a lower extremity amputee, a procedure that has opened new avenues for mobility and quality of life for those facing limb loss. The episode further dissects Dr. Allison's contributions to surgical technology. His role in the development of innovative implant systems—such as the Patriot Trans-Femoral and Trans-Tibial Osseointegration (OI) Implants, the Proximal Tibia Endoprosthetic Implant, and the Tribute Minimally Invasive/Bone Preserving Hip Arthroplasty Femoral Stem—cements his status as a transformative figure in orthopedic oncology. His research, which continues to influence the field through its publication in leading medical journals, underscores the relentless pursuit of improvement that defines modern medicine. Adding a layer of engaging narrative to the technical discourse, the program welcomes back Gina Grad, the renowned radio personality, author, and podcast host celebrated for her work on The Adam Carolla Show and her children's book, My Extra Mom, which helps kids understand and cope with blended family dynamics. Grad's return infuses the episode with her signature authenticity and knack for turning intricate topics into compelling storytelling, ensuring that viewers not only grasp the significance of these medical advancements but also appreciate their tangible impact on patients' lives. The New Frontiers episodes are currently scheduled to air on Bloomberg Television. Additionally, the series will be accessible on-demand through platforms such as Amazon, Vimeo, YouTube, Roku, Tumblr, X, Brighteon, Facebook, Rumble, Dailymotion, Newsbreak, and more. New Frontiers remains dedicated to demystifying the work of the innovators driving the future of medicine, technology, and industry. Following its live broadcast, the episode will be available on-demand, extending its reach to a global audience eager to witness firsthand the strides being made in orthopedic surgery. For more details on Dr. Daniel C. Allison, MD, FACS, please visit Planet TV Studios X Other
Associated Press
26-02-2025
- Business
- Associated Press
Planet TV Studios Announces 'New Frontiers' Episode Featuring NeOnc Technologies Holdings, Inc. – March 1st on Bloomberg
Planet TV Studios proudly serves as the exclusive sponsor of the New Frontiers series. NeOnc Technologies Holdings in New Frontiers Episode March 1st Bloomberg. WESTLAKE VILLAGE, CA, UNITED STATES, February 26, 2025 / / -- Planet TV Studios Announces Upcoming 'New Frontiers' Episode Featuring NeOnc Technologies Holdings, Inc. – Airing March 1, March 15, and April 12, 2025, on Bloomberg Planet TV Studios is set to premiere its latest episode of New Frontiers, featuring an in-depth look at NeOnc Technologies Holdings, Inc., a company leading the charge in the fight against brain cancer. Airing on Bloomberg at 5:00 PM ET on March 1, March 15, and April 12, 2025, this episode, titled New Frontiers: Highlighting Emerging Technologies, will explore NeOnc's bold approach to neurosurgery and its development of promising intranasal therapies designed to target malignant brain tumors more effectively. A Closer Look at NeOnc Technologies Holdings, Inc. NeOnc Technologies Holdings, Inc., founded by renowned neurosurgeon Dr. Thomas Chen, is tackling one of the most formidable challenges in medicine—treating brain cancer while overcoming the limitations of the blood-brain barrier. Traditional treatments often struggle to penetrate this barrier, but NeOnc's development-stage intranasal drug delivery platform aims to deliver therapeutic agents directly to the brain. At the center of NeOnc's research are two promising treatments: NEO100 and NEO212. NEO100, a purified form of perillyl alcohol, and NEO212, a combination of temozolomide (TMZ) and perillyl alcohol, have been designed to reach tumors with the potential for enhanced effectiveness and fewer side effects. Early clinical trials suggest that this approach could change the way patients with glioblastoma multiforme and metastatic brain tumors are treated. 'Brain cancer patients have long faced limited options, and our goal is to provide a meaningful alternative,' said Dr. Chen. 'By developing a treatment that could bypass the blood-brain barrier through intranasal delivery, we hope to offer a pathway to better outcomes for those battling this disease.' Beyond research, NeOnc Technologies Holdings, Inc. is also preparing to go public via a direct listing on the Nasdaq in the first quarter of 2025—a move that could accelerate its efforts to refine and expand its treatments. Returning Host Gina Grad Brings Insight and Expertise Planet TV Studios is excited to welcome back acclaimed broadcaster Gina Grad as the host of this New Frontiers episode. Known for her work on The Adam Carolla Show and as the author of My Extra Mom, Grad has built a reputation for her ability to engage audiences with thoughtful, compelling storytelling. Her deep curiosity and talent for breaking down complex subjects make her the ideal guide for viewers eager to understand the latest advancements in neurosurgery and brain cancer treatment. 'I'm thrilled to be part of another season of New Frontiers,' said Grad. 'The stories we tell aren't just about science and medicine—they're about people, hope, and the drive to improve lives.' How to Watch The New Frontiers episode featuring NeOnc Technologies Holdings, Inc. will air nationally on Bloomberg at 5:00 PM ET on March 1, March 15, and April 12, 2025. Following the broadcast, the episode will be available for on-demand streaming through Amazon, Vimeo, YouTube, Facebook, and Roku. For details on New Frontiers and other programming from Planet TV Studios, visit or contact Christian Alain at 888-210-4292 x100 or [email protected]. Christian Kelch Planet TV Studios X LinkedIn Instagram Other Legal Disclaimer:
